Invasive Ductal Carcinoma Therapeutics Market Report 2026

The invasive ductal carcinoma therapeutics market size has grown strongly in recent years. It will grow from $9.03 billion in 2025 to $9.83 billion in 2026 at a compound annual growth rate (CAGR) of 8.8%. The growth in the historic period can be attributed to increasing breast cancer incidence rates, wider availability of chemotherapy regimens, expansion of hospital oncology departments, increased adoption of hormone therapy, improved cancer screening practices.

The invasive ductal carcinoma therapeutics market size is expected to see strong growth in the next few years. It will grow to $13.6 billion in 2030 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to growing development of novel targeted drugs, increasing use of biomarker-driven treatment selection, expansion of precision oncology trials, rising focus on reducing recurrence rates, advancement of immuno-oncology combinations. Major trends in the forecast period include increasing use of targeted and hormone-based therapies, rising adoption of her2-targeted treatments, growing integration of personalized oncology regimens, expansion of combination therapy approaches, enhanced focus on early-stage treatment optimization.

The increasing incidence of breast cancer is anticipated to drive the growth of the invasive ductal carcinoma therapeutics market in the coming years. Breast cancer is a disease characterized by the uncontrolled growth of cells in the breast, forming a malignant tumor that can invade nearby tissues or spread to other parts of the body. The rise in breast cancer cases is largely attributed to lifestyle-related factors such as obesity and physical inactivity, which elevate the risk of malignant tumor development in breast tissue. Invasive ductal carcinoma therapeutics address breast cancer by providing targeted and effective treatment options, making them critical for managing the most prevalent form of breast cancer. These therapies help limit tumor growth and metastasis through precision-based medicines, thereby improving patient outcomes and quality of life. For example, according to the American Cancer Society Facts and Figures, a US-based nonprofit organization, new breast cancer cases increased from 300,590 in 2023 to 313,510 in 2024. Therefore, the rising incidence of breast cancer is fueling the growth of the invasive ductal carcinoma therapeutics market.

Major companies operating in the invasive ductal carcinoma (IDC) therapeutics market are concentrating on the development of innovative treatments, such as antibody-drug conjugates, to enhance targeted treatment effectiveness while minimizing adverse effects. Antibody-drug conjugates (ADCs) are targeted cancer therapies composed of an antibody linked to a cytotoxic agent, engineered to deliver the drug directly to cancer cells while limiting damage to healthy tissues. For instance, in January 2024, AstraZeneca Pharma India Limited, an India-based pharmaceutical company, in partnership with Daiichi Sankyo Company, Limited, a Japan-based pharmaceutical company, introduced trastuzumab deruxtecan. This antibody-drug conjugate therapy is intended for adult patients with unresectable or metastatic HER2-positive breast cancer. It functions by delivering a powerful topoisomerase I inhibitor, deruxtecan, directly to HER2-expressing cancer cells, leading to targeted DNA damage and cancer cell death.

In December 2024, Pfizer Inc., a US-based pharmaceutical company, acquired Seagen Inc. for $43 billion. Through this acquisition, Pfizer aims to enhance its leadership position in oncology by expanding its cancer therapy portfolio, accelerating the development of innovative treatments, and supporting long-term growth in the cancer treatment market. Seagen Inc. is a US-based biotechnology company focused on developing targeted therapies for invasive ductal carcinoma.

Major companies operating in the invasive ductal carcinoma therapeutics market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck And Co. Inc., AbbVie Inc., Bayer AG, Novartis International AG, AstraZeneca plc, Sanofi S.A., Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Macrogenics Inc., Celldex Therapeutics Inc., Johnson & Johnson, GlaxoSmithKline plc, Genzyme Corporation, Onyx Pharmaceuticals Inc., BioNumerik Pharmaceuticals Inc., Puma Biotechnology, Teva Pharmaceutical Industries Ltd., Biocon Limited.

North America was the largest region in the invasive ductal carcinoma therapeutics market in 2025. The regions covered in the invasive ductal carcinoma therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the invasive ductal carcinoma therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the invasive ductal carcinoma therapeutics market by increasing costs of imported oncology drugs, monoclonal antibodies, active pharmaceutical ingredients, and diagnostic testing kits. Hospitals and oncology clinics in North America and Europe are most affected due to reliance on imported cancer therapeutics, while Asia-Pacific faces pricing pressure on biologic drug supply chains. These tariffs are increasing treatment costs and influencing therapy accessibility. However, they are also driving domestic pharmaceutical manufacturing, regional clinical trial investments, and local production of oncology medications, strengthening long-term treatment availability.

The invasive ductal carcinoma therapeutics market research report is one of a series of new reports that provides invasive ductal carcinoma therapeutics market statistics, including invasive ductal carcinoma therapeutics industry global market size, regional shares, competitors with a invasive ductal carcinoma therapeutics market share, detailed invasive ductal carcinoma therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the invasive ductal carcinoma therapeutics industry. This invasive ductal carcinoma therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Invasive ductal carcinoma (IDC) therapeutics refers to medical treatments used to manage and treat invasive ductal carcinoma (IDC), a common form of breast cancer that originates in the milk ducts and spreads to surrounding tissues. The primary objective of these therapeutics is to eliminate or destroy cancer cells, prevent disease spread or recurrence, and improve patient survival and quality of life. These treatments include surgery, chemotherapy, and radiation therapy.

The primary drug types of invasive ductal carcinoma therapeutics include targeted therapy and hormone therapy. Targeted therapy involves treatments that selectively attack cancer cells based on specific molecular markers or genetic characteristics of the tumor, while largely sparing normal cells. The major cancer subtypes treated include hormone receptor-positive, human epidermal growth factor receptor 2 (HER2+)-positive, and triple-negative breast cancer, with end users consisting of hospitals, oncology clinics, and other healthcare settings.

The invasive ductal carcinoma therapeutics market consists of revenues earned by entities by providing services such as diagnostic imaging, biopsy procedures, hormone therapy, immunotherapy, and post-treatment monitoring and support care. The market value includes the value of related goods sold by the service provider or included within the service offering. The invasive ductal carcinoma therapeutics market also includes sales of diagnostic kits, biopsy tools, and medical devices used in surgical and radiation treatments. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.